Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
85001-0101-01 85001-0101 Zidesamtinib JIDEYTRO 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, ALK, TRK Oral Jul 22, 2026 In Use
85001-0102-01 85001-0102 Zidesamtinib JIDEYTRO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, ALK, TRK Oral Jul 22, 2026 In Use
68071-3738-03 68071-3738 PREDNISONE PREDNISONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jul 21, 2026 In Use
69448-0009-63 69448-0009 Filgrastim-laha FILKRI 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Jul 15, 2026 In Use
69448-0008-03 69448-0008 Filgrastim-laha FILKRI 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Jul 15, 2026 In Use
83831-0164-10 83831-0164 Fluorouracil FAVLYXA 25.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jul 15, 2026 In Use
68001-0708-25 68001-0708 Palonosetron Hydrochloride Palonosetron 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Jul 15, 2026 In Use
69448-0009-03 69448-0009 Filgrastim-laha FILKRI 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Jul 15, 2026 In Use
31722-0783-30 31722-0783 Afatinib Afatinib 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jul 14, 2026 In Use
31722-0781-30 31722-0781 Afatinib Afatinib 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR, HER2, HER4 Oral Jul 14, 2026 In Use
31722-0782-30 31722-0782 Afatinib Afatinib 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR, HER2, HER4 Oral Jul 14, 2026 In Use
84577-0751-01 84577-0751 Gedatolisib REVTORPYK 180.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR, PI3K (⍺,β,ƍ,γ) Intravenous Jul 14, 2026 In Use
72579-0125-00 72579-0125 Tislelizumab-jsgr TEVIMBRA 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Jul 13, 2026 In Use
69448-0022-63 69448-0022 Denosumab-desu JUBEREQ 70.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jul 13, 2026 In Use
00024-0674-01 00024-0674 Isatuximab-irfc Sarclisa Escena 140.0 mg/mL Immunotherapy Monoclonal Antibody CD38 Subcutaneous Jul 9, 2026 In Use
87441-0088-01 87441-0088 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 8, 2026 In Use
70404-0077-16 70404-0077 Prednisolone oral Prednisolone 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jul 8, 2026 In Use
70404-0077-14 70404-0077 Prednisolone oral Prednisolone 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jul 8, 2026 In Use
69448-0021-63 69448-0021 Denosumab-desu OSVYRTI 60.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jul 6, 2026 In Use
82249-0021-30 82249-0021 IMATINIB MESYLATE IMATINIB MESYLATE 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jul 3, 2026 In Use
82249-0020-90 82249-0020 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jul 3, 2026 In Use
69339-0366-45 69339-0366 CARBOPLATIN CARBOPLATIN 450.0 mg/45mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jul 2, 2026 In Use
69339-0367-60 69339-0367 CARBOPLATIN CARBOPLATIN 600.0 mg/60mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jul 2, 2026 In Use
69339-0364-05 69339-0364 CARBOPLATIN CARBOPLATIN 50.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jul 2, 2026 In Use
83831-0159-02 83831-0159 Fulvestrant CLIGAVYX 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Jul 1, 2026 In Use

Found 12611 results — Export these results